This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Occhipinti, D. J. Articles by Rodvold, K. A. Search for Related Content PubMed PubMed Citation Articles by Occhipinti, D. J. Articles by Rodvold, K. A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., 11 1997, 2511-2517, Vol 41, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin- tazobactam regimens

DJ Occhipinti, SL Pendland, LL Schoonover, EB Rypins, LH Danziger and KA Rodvold
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612, USA.

The pharmacokinetics and pharmacodynamics of two multiple-dose regimens of piperacillin-tazobactam (3.375 g every 6 h and 4.5 g every 8 h) were evaluated at steady state for 12 healthy adult volunteers. Inhibitory and bactericidal activities for the two regimens were determined with five American Type Culture Collection (ATCC) organisms (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Bacteroides fragilis). The percentage of time that plasma concentrations remained above the MIC (T > MIC) for each organism and dosage regimen was calculated. Areas under the inhibitory (AUIC0-24) and bactericidal activity (AUBC0-24) curves were calculated with the trapezoidal rule by using the reciprocal of the inhibitory and bactericidal titers determined for each dosage regimen. In order to assess the validity of predicted measures of bactericidal (AUC0-24/MBC) and inhibitory (AUC0-24/MIC) activity to determine bacteriological response to beta-lactam antimicrobial agents, AUC0-24/MBC and AUC0- 24/MIC values were compared with measured AUBC0-24 and AUIC0-24 values. Total body clearance values were equivalent for piperacillin (183.96 +/- 22.66 versus 181.72 +/- 19.54 ml/min/1.73 m2, P > 0.05) and tazobactam (184.71 +/- 19.89 versus 184.87 +/- 18.35 ml/min/1.73 m2, P > 0.05) following the administration of the 3.375-g-every-6-h and 4.5-g-every-8- h dosages, respectively. Comparison of area under the plasma concentration-time curve (AUC0-24) for piperacillin (967.74 +/- 135.56 microg x h/ml versus 978.88 +/- 140.96 microg x h/ml) and tazobactam (120.14 +/- 15.78 microg x h/ml versus 120.01 +/- 16.22 microg x h/ml) revealed no significant differences (P > 0.05) between the 3.375-g- every-6-h and 4.5-g-every-8-h regimens, respectively. Both regimens provided T > MIC values of > 60% for all organisms tested. Measured values of bactericidal (AUBC) and inhibitory (AUIC) activity were significantly different (P < 0.05) from predicted values (AUC0-24/MBC and AUC0-24/MIC) for all organisms studied with the exception of the bactericidal activity for P. aeruginosa and S. aureus. Additionally, ATCC organisms possessing the same MICs and MBCs exhibited great differences in measured AUBC0-24 and AUIC0-24 values. Reasons for this difference may be inherent differences in organism specific susceptibility.

This article has been cited by other articles:

• Frei, C. R., Wiederhold, N. P., Burgess, D. S. (2008). Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61: 621-628 [Abstract] [Full Text]  
• Gavin, P. J., Suseno, M. T., Thomson, R. B. Jr., Gaydos, J. M., Pierson, C. L., Halstead, D. C., Aslanzadeh, J., Brecher, S., Rotstein, C., Brossette, S. E., Peterson, L. R. (2006). Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella Species.. Antimicrob. Agents Chemother. 50: 2244-2247 [Abstract] [Full Text]  
• Burgess, D. S., Frei, C. R. (2005). Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 56: 893-898 [Abstract] [Full Text]  
• Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., Drusano, G. L. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55: 601-607 [Abstract] [Full Text]  
• Masterton, R. G., Kuti, J. L., Turner, P. J., Nicolau, D. P. (2005). The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55: 71-77 [Abstract] [Full Text]  
• Lodise, T. P. Jr., Lomaestro, B., Rodvold, K. A., Danziger, L. H., Drusano, G. L. (2004). Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. Antimicrob. Agents Chemother. 48: 4718-4724 [Abstract] [Full Text]  
• Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2004). Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2470 [Abstract] [Full Text]  
• Mueller, S. C., Majcher-Peszynska, J., Hickstein, H., Francke, A., Pertschy, A., Schulz, M., Mundkowski, R., Drewelow, B. (2002). Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis. Antimicrob. Agents Chemother. 46: 1557-1560 [Abstract] [Full Text]  
• Kim, M.-K., Xuan, D., Quintiliani, R., Nightingale, C. H., Nicolau, D. P. (2001). Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother 48: 259-267 [Abstract] [Full Text]  
• Auclair, B., Ducharme, M. P. (1999). Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Doses. Antimicrob. Agents Chemother. 43: 1465-1468 [Abstract] [Full Text]